EX-Trade Interview: Open-Pod E-Cigarettes Regain Market Attention with OXVA's Swift Ascent

Sep.20.2024
EX-Trade Interview: Open-Pod E-Cigarettes Regain Market Attention with OXVA's Swift Ascent
German e-cigarette market trends and future challenges were discussed at Dortmund tobacco exhibition with EX-Trade VP Christopher Kolster.

On September 20, in Dortmund, Germany, the 2Firsts team engaged in a deep discussion with Christopher Kolster, Sales Deputy Director of EX-Trade, a German e-cigarette distributor, at a tobacco exhibition. Kolster shared insights on the current state and future trends of the German e-cigarette market, discussing changes in consumer demand, brand development strategies, and key drivers of the market.

EX-Trade Interview: Open-Pod E-Cigarettes Regain Market Attention with OXVA's Swift Ascent
Cooperative e-cigarette brand | Image source: EX-Trade


Market demand in Germany is stabilizing.

EX-Trade Interview: Open-Pod E-Cigarettes Regain Market Attention with OXVA's Swift Ascent
EX-Trade store | Image source: EX-Trade


Kolster, founded in 2006, originally started as a video game wholesaler and has since expanded its product range. Since the end of 2011, the company has been selling e-cigarettes and related accessories, and is currently one of the top three e-cigarette distributors in Germany.


He stated that the age distribution of e-cigarette consumers in Germany and Europe is wide, covering people from 18 to 60 years old. Kolster pointed out that although e-cigarettes are relatively low-priced in Europe, consumers are not concentrated in a specific age group but are in a "mixed" state. Over the past year, market demand has fluctuated minimally and has generally remained stable.


Open systems are once again becoming the focus of the market, with OXVA being the most popular.


In recent years, the e-cigarette market in Germany has experienced several waves of product trends. Initially, open system e-cigarettes with high wattage were highly popular, followed by disposable e-cigarettes becoming the mainstream. However, sales of disposable e-cigarettes have recently begun to decline, and the market is shifting back towards open system products.


When discussing the popularity of large capacity pod system products that comply with TPD regulations in the UK market in recent years, Kolster has said that this trend may be reflected in the German market. However, according to EX-Trade's sales data, the demand for disposable e-cigarettes is decreasing, and open-system products are once again becoming the focus of the market. He mentioned that five or six years ago, the German market experienced a similar trend of large capacity products, and now this trend is returning.


According to a witness, currently the hottest product being sold by EX-Trade is the OXVA brand e-cigarette. Kolster believes that the sales increase for OXVA is due to its quality, taste experience, and marketing strategies. He emphasizes that consumers are increasingly valuing the user experience, which is helping OXVA stand out in the competitive market.


When choosing collaboration brands, Kolster emphasizes that quality and innovation are core factors. He mentioned that emerging brands like YOOZ, with innovative product features such as calling functions, are changing the market landscape in Germany. At the same time, well-known brands like UWELL, OXVA, and Geek Vape are also actively seeking to gain market share.


Kolster believes that the future market will see multiple brands coexisting, rather than one brand monopolizing.


Successful products are a combination of design, distribution, and innovation.


Looking to the future, Kolster believes that the success of the e-cigarette market depends on the organic combination of product design, distribution channel strategy, and pricing positioning.


He predicts that with ongoing technological innovation and changes in consumer demand, more new brands and products will emerge in the German market. Brands can only stand unbeatable in fierce market competition by continually improving product quality and innovation capabilities.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI nicotine pouch brand Nordic Spirit has entered a long-term partnership with Manchester’s Co-op Live, becoming the venue’s Official Nicotine Pouch Partner. The 23,500-capacity venue is the UK’s largest indoor live entertainment arena. Nordic Spirit will run in-venue activations for existing adult nicotine consumers and sell products at selected arena bars. The agreement was entered into before the relevant UK sponsorship restrictions were introduced, while the government intends to implement a comprehensive ban on advertising and sponsorship of vaping and nicotine products from June 1, 2027.
Sep.07
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA Issues First U.S. Clinical Guidance on Vaping for Smoking Cessation, Urging Complete Switch From Cigarettes
JAMA has published a Special Communication offering systematic recommendations for U.S.-based clinicians on the use of nicotine e-cigarettes in adult smoking cessation. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the paper recommends including e-cigarettes alongside FDA-approved cessation medications in risk-benefit discussions. It cites high-certainty evidence that nicotine e-cigarettes achieve higher quit rates than nicotine replacement therapy and evidence suggesting efficacy comparable to highly effective medications such as varenicline and cytisine. For adults who choose vaping to quit, the authors recommend FDA-authorized products, sufficient nicotine delivery and a rapid, complete transition away from cigarettes rather than prolonged dual use.
Aug.13
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11